NO20092616L - Antifolatmiddelkombinasjoner i behandling av kreft - Google Patents

Antifolatmiddelkombinasjoner i behandling av kreft

Info

Publication number
NO20092616L
NO20092616L NO20092616A NO20092616A NO20092616L NO 20092616 L NO20092616 L NO 20092616L NO 20092616 A NO20092616 A NO 20092616A NO 20092616 A NO20092616 A NO 20092616A NO 20092616 L NO20092616 L NO 20092616L
Authority
NO
Norway
Prior art keywords
enhance
treatment
cancer
certain
agent combinations
Prior art date
Application number
NO20092616A
Other languages
English (en)
Other versions
NO344316B1 (no
Inventor
Charles P Theuer
Bonne Jean Adams
Original Assignee
Tracon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39775383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092616(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tracon Pharmaceuticals Inc filed Critical Tracon Pharmaceuticals Inc
Publication of NO20092616L publication Critical patent/NO20092616L/no
Publication of NO344316B1 publication Critical patent/NO344316B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Preparater og metoder anvendelige ved behandling av visse kreftformer. Metoden omfatter administrering til en pasient som mottar et antifolat anticancer middel metoksyamin administrert i en mengde tilstrekkelig til å forbedre eller øke effekten av antifolat anticancermidlet. Denne søknaden er delvis basert på erkjennelsen av at visse molekyler som målsøker abasiske lesjoner eller AP seter i DNA forbedrer, forøker eller forsterker den kjemoterapeutiske effektivitet av visse anticancer midler. 1
NO20092616A 2006-12-29 2009-07-10 Anvendelse av antifolatmiddelkombinasjoner i behandling av kreft NO344316B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87783606P 2006-12-29 2006-12-29
US88326607P 2007-01-03 2007-01-03
US88395907P 2007-01-08 2007-01-08
PCT/US2007/088666 WO2008083107A2 (en) 2006-12-29 2007-12-21 Antifolate agent combinations in the treatment of cancer

Publications (2)

Publication Number Publication Date
NO20092616L true NO20092616L (no) 2009-09-22
NO344316B1 NO344316B1 (no) 2019-11-04

Family

ID=39775383

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092616A NO344316B1 (no) 2006-12-29 2009-07-10 Anvendelse av antifolatmiddelkombinasjoner i behandling av kreft

Country Status (15)

Country Link
US (1) US8017618B2 (no)
EP (1) EP2173333B1 (no)
JP (1) JP5249239B2 (no)
KR (1) KR101195366B1 (no)
CN (2) CN102014887A (no)
AU (1) AU2007339918B2 (no)
BR (1) BRPI0722053A2 (no)
CA (1) CA2674075C (no)
ES (1) ES2688938T3 (no)
GB (1) GB2453011B (no)
HK (1) HK1215683A1 (no)
IL (1) IL199609A0 (no)
MX (1) MX2009007144A (no)
NO (1) NO344316B1 (no)
WO (1) WO2008083107A2 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2602475T3 (es) * 2010-04-15 2017-02-21 Tracon Pharmaceuticals, Inc. Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
US10725042B2 (en) * 2012-05-22 2020-07-28 Case Western Reserve University Methods of diagnosing and treating cancer
JP2014001204A (ja) * 2012-05-23 2014-01-09 Kumamoto Univ 腫瘍細胞選択的抗がん剤
ES2853973T3 (es) * 2013-04-09 2021-09-20 The Board Of Trustees Of The Univ Of Illionis Uso de DNQ o DNQ-87 en combinación con un inhibidor de PARP1 para el tratamiento del cáncer
WO2014167585A1 (en) * 2013-04-12 2014-10-16 Actavis Group Ptc Ehf. Pemetrexed formulation
JP6768786B2 (ja) * 2015-07-30 2020-10-14 エクスプレッション、パソロジー、インコーポレイテッドＥｘｐｒｅｓｓｉｏｎ Ｐａｔｈｏｌｏｇｙ， Ｉｎｃ． 最適な癌療法のためのＦＲ−αおよびＧＡＲＴタンパク質の定量
US11344628B2 (en) * 2016-08-12 2022-05-31 L.E.A.F. Holdings Group Llc Alpha polyglutamated antifolates and uses thereof
WO2018147437A1 (ja) * 2017-02-10 2018-08-16 学校法人神戸学院 低分子医薬化合物の経粘膜吸収促進剤
KR102040034B1 (ko) * 2017-12-13 2019-11-05 주식회사 아이큐어비앤피 페메트렉시드를 포함하는 경구용 약학 조성물 및 이의 제조방법
JP7490240B2 (ja) * 2018-02-07 2024-05-27 エル．イー．エー．エフ． ホールディングス グループ エルエルシー ガンマポリグルタミン酸化葉酸代謝拮抗薬およびその使用
EP3749311A4 (en) * 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC GAMMA POLYGLUTAMATED PEMETREXED AND USES THEREOF
EP3752156A4 (en) 2018-02-14 2021-10-27 L.E.A.F Holdings Group LLC PRALATREXATE GAMMA-POLYGLUTAMATE AND ASSOCIATED USES
EP3755335A4 (en) 2018-02-14 2022-06-22 L.E.A.F Holdings Group LLC GAMMA POLYGLUTAMIC TETRAHYDROFOLATES AND THEIR USES
JP7364836B2 (ja) 2019-01-25 2023-10-19 大和紡績株式会社 水硬性硬化体添加用集束繊維、それを含むプレミックスセメント組成物及び水硬性硬化体、並びにその製造方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3386597A (en) 1996-06-11 1998-01-07 Advanced Research And Technology Institute, Inc. Methods and compositions for the use of apurinic/apyrimidinic endonucleases
US6406917B1 (en) 1996-06-11 2002-06-18 Advanced Research And Technology Institute Methods and compositions for the use of apurinic/apyrimidinic endonucleases
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
WO2003007955A2 (en) 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
JP2005517007A (ja) * 2002-02-07 2005-06-09 アクシス・ファーマスーティカルズ ヒストンデアセチラーゼ阻害剤としての新規二環式ヒドロキサメート
GB2385523B (en) * 2002-02-25 2004-01-07 Ronan Anthony Byrne Descent apparatus
US7785578B2 (en) 2002-10-11 2010-08-31 Aciont, Inc. Non-invasive ocular drug delivery
GB0226370D0 (en) * 2002-11-12 2002-12-18 Novartis Ag Organic compounds
WO2005027907A1 (en) 2003-09-17 2005-03-31 Icos Corporation Use of chk1 inhibitors to control cell proliferation
TWI338000B (en) 2003-12-01 2011-03-01 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
US8246949B2 (en) 2004-10-27 2012-08-21 Aciont, Inc. Methods and devices for sustained in-vivo release of an active agent
US20070082841A1 (en) 2005-09-27 2007-04-12 Aciont, Inc. Ocular administration of immunosuppressive agents
WO2007041593A2 (en) 2005-10-03 2007-04-12 Combinatorx, Incorporated Anti-scarring drug combinations and use thereof
CN100500215C (zh) 2006-01-23 2009-06-17 济南帅华医药科技有限公司 含氨甲喋呤及其增效剂的缓释注射剂

Also Published As

Publication number Publication date
JP5249239B2 (ja) 2013-07-31
CA2674075C (en) 2012-10-30
HK1215683A1 (zh) 2016-09-09
CN102014887A (zh) 2011-04-13
CA2674075A1 (en) 2008-07-10
MX2009007144A (es) 2009-12-18
AU2007339918A1 (en) 2008-07-10
WO2008083107A3 (en) 2010-01-21
GB2453011A (en) 2009-03-25
KR20090110843A (ko) 2009-10-22
IL199609A0 (en) 2010-05-17
GB2453011B (en) 2010-06-23
AU2007339918B2 (en) 2011-06-02
NO344316B1 (no) 2019-11-04
JP2010538967A (ja) 2010-12-16
BRPI0722053A2 (pt) 2018-04-17
ES2688938T3 (es) 2018-11-07
GB0812013D0 (en) 2008-08-06
KR101195366B1 (ko) 2012-11-21
US8017618B2 (en) 2011-09-13
US20080234298A1 (en) 2008-09-25
EP2173333A2 (en) 2010-04-14
CN104958299A (zh) 2015-10-07
EP2173333B1 (en) 2018-06-27
WO2008083107A2 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
NO20092616L (no) Antifolatmiddelkombinasjoner i behandling av kreft
WO2004065423A3 (de) Erkennungsmoleküle zur behandlung und detektion von tumoren
LUC00011I2 (no)
HK1102991A1 (en) Pharmaceutical formulation of decitabine
EP3248600B8 (en) Combinations and modes of administration of therapeutic agents and combination therapy
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
WO2004087153A3 (en) Use of organic compounds for immunopotentiation
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
WO2005118601A3 (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2009098464A3 (en) Use of g-rich oligonucleotides for treating neoplastic diseases
WO2006128740A3 (en) Anti-vascular methods and therapies employing lysyl oxidase inhibitors
WO2007008490A3 (en) Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
WO2007146375A3 (en) Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer
UA96614C2 (ru) Комбинации антифолатного агента в лечении рака
MD3222G2 (ro) Metodă de diagnostic al cancerului endometrial
SE0401066D0 (sv) Chemical Derivatives

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TRACON PHARMACEUTICALS, US